China gene-editing startup YolTech secures $70 million funding ahead of Hong Kong IPO plans
read at Endpoints ↗DealPositive
YolTech Therapeutics, a Chinese company focused on CRISPR gene-editing therapies, announced it has closed a $70 million financing round, the largest in its history.
The capital will be used to advance its pipeline of CRISPR-based treatments and to support the company’s planned initial public offering on the Hong Kong Stock Exchange.
The fundraising comes as many U.S. gene-editing firms are scaling back, highlighting YolTech’s aggressive growth strategy in the Chinese biotech sector.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “China gene editing startup YolTech raises $70M to move CRISPR therapies forward”
read at Endpoints ↗104 words · retrieved Jun 3
comments(0)
5-min edit window · permanent after that